Prometic Life Scie Com Npv (PFSCF) Lowered to “Hold” at Zacks Investment Research
Prometic Life Scie Com Npv (NASDAQ:PFSCF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday.
According to Zacks, “ProMetic Life Sciences Inc. is a biopharmaceutical company. The company is involved in bioseparations, plasma-derived therapeutics and small-molecule drug development. Its operating segment consists of Therapeutics and Protein Technology. Therapeutics segment products include PBI-4050 for treatment of fibrosis with chronic kidney diseases, certain cancers and side effects associated with chemotherapy; PBI-4419, an anti-fibrotic and anti-inflammatory compound for kidney injury and chronic kidney diseases and PBI-1402 for the treatment of anemia indications. Protein Technology segment provides plasma protein purification system, bioseparation products and prion capture/pathogen removal technology platform. ProMetic Life Sciences Inc. is headquartered in Laval, Canada. “
Shares of Prometic Life Scie Com Npv (NASDAQ:PFSCF) opened at 2.186 on Wednesday. Prometic Life Scie Com Npv has a 12-month low of $1.29 and a 12-month high of $2.77. The stock’s 50 day moving average price is $2.23 and its 200-day moving average price is $2.33. The firm’s market capitalization is $1.32 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/prometic-life-scie-com-npv-pfscf-lowered-to-hold-at-zacks-investment-research.html
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prometic Life Scie Com Npv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prometic Life Scie Com Npv and related companies with MarketBeat.com's FREE daily email newsletter.